[go: up one dir, main page]

AR085905A1 - Una combinacion farmaceutica sinergistica para el tratamiento del cancer de pancreas - Google Patents

Una combinacion farmaceutica sinergistica para el tratamiento del cancer de pancreas

Info

Publication number
AR085905A1
AR085905A1 ARP120100840A ARP120100840A AR085905A1 AR 085905 A1 AR085905 A1 AR 085905A1 AR P120100840 A ARP120100840 A AR P120100840A AR P120100840 A ARP120100840 A AR P120100840A AR 085905 A1 AR085905 A1 AR 085905A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical combination
treatment
pancreas cancer
rfde
synergistic pharmaceutical
Prior art date
Application number
ARP120100840A
Other languages
English (en)
Inventor
Veena Agarwal
Arun Balakrishnan
Kalpana Joshi
Giridharan Periyasamy
Maggie Rathos
Somesh Sharma
Original Assignee
Piramal Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Life Sciences Ltd filed Critical Piramal Life Sciences Ltd
Publication of AR085905A1 publication Critical patent/AR085905A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Una combinación farmacéutica que comprende un inhibidor QDC seleccionado de los compuestos de la fórmula (1), en donde Ar es un grupo fenilo, que está no sustituido o sustituido por 1, 2, ó 3 sustituyentes idénticos o diferentes seleccionados de: halógeno; nitro, ciano, alquilo C1-4, trifluorometilo, hidroxilo o alcoxi C1-4; o una sal o un solvato farmacéuticamente aceptable de los mismos; y un compuesto capaz de inhibir la actividad quinasa del receptor de factor de desarrollo epidérmico (RFDE).Reivindicación 7: La combinación farmacéutica de acuerdo con la reivindicación 1, en donde el compuesto capaz de inhibir la actividad quinasa del receptor del factor de desarrollo epidérmico (RFDE) se selecciona de erlotinib o lapatinib. Reivindicación 10: La combinación farmacéutica de acuerdo con la reivindicación 1; en donde la mencionada combinación asimismo comprende gemcitabina.
ARP120100840A 2011-03-14 2012-03-14 Una combinacion farmaceutica sinergistica para el tratamiento del cancer de pancreas AR085905A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161452197P 2011-03-14 2011-03-14

Publications (1)

Publication Number Publication Date
AR085905A1 true AR085905A1 (es) 2013-11-06

Family

ID=45999898

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120100840A AR085905A1 (es) 2011-03-14 2012-03-14 Una combinacion farmaceutica sinergistica para el tratamiento del cancer de pancreas

Country Status (3)

Country Link
AR (1) AR085905A1 (es)
TW (1) TW201242597A (es)
WO (1) WO2012123889A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR096892A1 (es) 2013-07-12 2016-02-03 Piramal Entpr Ltd Una combinación farmacéutica para el tratamiento del melanoma
WO2015181737A1 (en) 2014-05-28 2015-12-03 Piramal Enterprises Limited Pharmaceutical combination for the treatment of cancer
WO2017160568A1 (en) 2016-03-16 2017-09-21 Eli Lilly And Company Combination therapy comprising the cdk4/6 inhibitor necitumumab and the egfr inhibitor abemaciclib for use in treating cancer
KR20210013155A (ko) * 2018-05-23 2021-02-03 지앙수 헨그루이 메디슨 컴퍼니 리미티드 종양 질환 치료용 약제의 제조에서 egfr 억제제와 조합된 cdk4/6 억제제의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
CA1264738A (en) 1984-12-04 1990-01-23 Eli Lilly And Company Treatment of tumors in mammals
JP2757348B2 (ja) 1996-04-18 1998-05-25 株式会社同仁化学研究所 新規水溶性テトラゾリウム塩化合物
US7884127B2 (en) 2002-07-08 2011-02-08 Pirimal Life Sciences Ltd. Inhibitors of cyclin dependent kinases and their use
TWI331034B (en) 2002-07-08 2010-10-01 Piramal Life Sciences Ltd Inhibitors of cyclin-dependent kinases and their use
EP2026805A1 (en) * 2006-05-08 2009-02-25 Astex Therapeutics Limited Pharmaceutical combinations of diazole derivatives for cancer treatment
US8563596B2 (en) 2006-06-21 2013-10-22 Piramal Enterprises Limited Enantiomerically pure compounds for the treatment of proliferative disorders
JP5006396B2 (ja) 2006-07-07 2012-08-22 ピラマル・ライフ・サイエンシーズ・リミテッド ピロリジン置換フラボンのエナンチオ選択的合成
EP2116246A1 (en) 2007-01-19 2009-11-11 Eisai R&D Management Co., Ltd. Composition for treatment of pancreatic cancer
US8822526B2 (en) 2007-05-15 2014-09-02 Piramal Enterprises Limited Synergistic pharmaceutical combination for the treatment of cancer
TWI461194B (zh) * 2009-05-05 2014-11-21 Piramal Entpr Ltd 吡咯啶取代黃酮作為輻射致敏劑

Also Published As

Publication number Publication date
WO2012123889A1 (en) 2012-09-20
TW201242597A (en) 2012-11-01

Similar Documents

Publication Publication Date Title
AR088175A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen
CR20150045A (es) Inhibidores de hepatitis c
CU24621B1 (es) Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5
MX386103B (es) Inhibidores de mcl-1 y metodos de uso de los mismos.
AR094314A1 (es) Inhibidores de fosfatidilinositol 3-cinasa
UY32490A (es) Inhibidores de beta-secretasa
EA201492170A1 (ru) Новые замещенные в цикле n-пиридиниламиды в качестве ингибиторов киназ
EA201101334A1 (ru) Новые соединения бензотиадиазепина, способ их приготовления и фармацевтические композиции, содержащие их
CR20110224A (es) Pirazolopirimidina inhibidor jak compuestos y metodos
AR064561A1 (es) Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina.
AR093244A1 (es) Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2
DOP2015000158A (es) Inhibidores de prmt5 y sus usos
AR063602A1 (es) Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos.
ECSP12011645A (es) Compuestos y métodos inhibidores de jak de pirazolopirimidina
ECSP12011910A (es) Derivados de imidazopiridina como inhibidores de jak
EA201301209A1 (ru) Производные пирролотриазинона в качестве ингибиторов p13k
BR112012001817B8 (pt) furazanobenzimidazóis, seu uso, processo de produção e composição farmacêutica
ES2657549T3 (es) Piridopirazinas sustituidas como nuevos inhibidores de SYK
AR086100A1 (es) Compuestos de cromenona y composiciones farmaceuticas que los contienen
BR112016028814A2 (pt) ?composição farmacêutica, métodos de tratamento de uma doença ou condição, de inibição de reações imunitárias ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, composto, um sal, um isômero, ou uma mistura farmaceuticamente aceitável do mesmo, e, uso de um composto, de um sal, de um isômero, ou de uma mistura farmaceuticamente aceitável do mesmo?
AR093408A1 (es) Derivados de oxazolidin-2-ona-pirimidina
AR069607A1 (es) Inhibidores de la estearoil-coa desaturasa
EA201490754A1 (ru) Производные карбамата/мочевины, содержащие пиперидиновые и пиперазиновые кольца, в качестве ингибиторов н3 рецептора
CO6362013A2 (es) Derivados de rifamicina
EA201591645A1 (ru) Hантагонисты, имеющие феноксипиперидиновое ядро в структуре

Legal Events

Date Code Title Description
FA Abandonment or withdrawal